651 results on '"Pour, L"'
Search Results
2. Monoklonální gamapatie klinického významu s osteosklerotickými ložisky – popis případu a přehled literatury.
3. Přehled histiocytárních a dendritických neoplazií dle 5. verze WHO klasifi kace krevních chorob z roku 2022.
4. Profylaktická osteosyntéza dlouhých kostí u pacientů s mnohočetným myelomem.
5. Poškození způsobená depozity monoklonálního imunoglobulinu typu IgM a lehkými řetězci u Waldenströmovy makroglobulinémie – popis případu a přehled literatury.
6. Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis
7. AB0036 HIGH THROUGHPUT siRNA EFFICACY SCREENING USING FLUORESCENCE SYSTEM
8. B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
9. B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
10. P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
11. Language recognition by convolutional neural networks
12. Standardizace 18F-FDG PET/CT u pacientů s mnohočetným myelomem: Společné doporučení České myelomové skupiny a České společnosti nukleární medicíny.
13. Waldenströmova makroglobulinemie – klinické projevy a přehled léčby včera, dnes a zítra.
14. Standardizace PET/CT u pacientů s mnohočetným myelomem – Společné doporučení České myelomové skupiny a České společnosti nukleární medicíny.
15. P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
16. PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
17. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
18. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
19. Proximal onychomycosis due to Malassezia furfur: a case report
20. Language recognition by convolutional neural networks.
21. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
22. Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients
23. ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
24. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
25. Subcutaneous Daratumumab (DARA SC) with Standard-ofCare (SoC) in Multiple Myeloma (MM) across therapy lines in phase 2 PLEIADES: Initial results with SoC Carfilzomib/Dexamethasone (D-Kd) and updated results with SoC Bortezomib/Melphalan/Prednisone (D-VMP) or Lenalidomide/Dexamethasone (D-Rd)
26. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
27. ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETASONE AND DARATUMUMAB OR BORTEZOMIB IN MULTIPLE RECYCLING / REFRACTORY MYELOMA (MMRR) TO AN IMMUNOMODULATOR AND/OR A PROTEASOMA INHIBITOR (IP): UPDATE OF EFFECTIVENESS AND SAFETY
28. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
29. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
30. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
31. Efficacy and safety of weekly carfilzomib (70 mg/m(2)), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
32. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
33. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
34. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
35. Pozvolný vzestup bilirubinu v průběhu léčby mnohočetného myelomu lenalidomidem, bortezomibem a dexametazonem (demaskování dříve nediagnostikovaného Gilbertova syndromu) a vymizení nekrobiotického xantogranulomu po dosažení kompletní remise myelomu
36. Retroperitoneální fibróza - diagnostika a léčba.
37. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
38. Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m(2) and Once-Weekly at 70 mg/m(2) in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies
39. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
40. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients
41. EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001
42. Erdheim-Chester disease and our experience with cladribine therapy in two patients: V719
43. The Correlation between NRF2Antioxidant Gene Expression and Sperm Quality in Asthenoteratozoospermia Men
44. Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data
45. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience
46. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
47. Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens: B228
48. High HGF Levels are Associated with Response to Bortezomib: B226
49. Dendritic Cells Immunotherapy: A Phase II Clinical Trial: A518
50. Better Efficacy/Toxicity Ratio of Velcade-Based Regimens: A251
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.